Wyss Institute at Harvard University

Learn about Gozde Basara's path to becoming a Biofabrication Engineer at the Wyss, from her early aspirations of becoming a car designer to realizing she wanted to find a way to help patients sooner by becoming a bridge between academia and industry.

We were thrilled to host a cohort of students from BioversityMA, a MassBio initiative, at the Wyss Institute last week. Bioversity provides students with technical and professional skill training to be ready for a variety of entry-level scientific operations jobs, propelling new talent into the field of biotech. ? Over the course of the afternoon, members of our community shared reflections on their own career paths, examples of current work around the Institute, and our shared passion for transformational research and innovation. Congratulations to this latest cohort of Bioversity graduates!?

It's #BrainAwarenessWeek. How can we improve brain health and more effectively diagnose and treat neurological and mental health disorders? At the Wyss, we're taking on this challenge by finding new ways to deliver therapeutics across the blood-brain barrier and developing new diagnostics and therapeutics for many diseases. Check out all of our brain-related work here: https://lnkd.in/euCt57Nj

We know that great innovation happens when diverse perspectives come together to solve grand challenges. That's why we're proud of our multidisciplinary team of researchers from around the world who are working together to achieve maximum impact. If you want to contribute your perspective, join our talent community to learn about jobs that match your skill set. https://bit.ly/Wyss-Gem

This Circular Vector (CV) protocol, developed by Wyss Core Faculty member George Church and Roman Oliynyk, introduces a synthetic, cell-free method to produce transfection-ready, small, double-stranded DNA templates for gRNA expression, suitable for diverse genome-editing purposes. Unlike conventional plasmid-based systems, this approach shortens the preparation time for expression vectors to just a few hours, yielding a gRNA-expression template free from bacterial endotoxins and nucleic acid impurities. This work was published in Nature Portfolio Protocols. https://lnkd.in/e2257-85

We're so excited to announce that the Wyss' DoriVac Technology has been chosen to compete in #STATMadness, a bracketed competition from STAT to find the most innovative research development in the country! The first round closes tomorrow, so vote for us to advance to round two! https://lnkd.in/e5SDKQKC

Happy #InternationalWomensDay! We know that incredible women from Marie Curie to Rosalind Franklin to Katherine Johnson have made groundbreaking or history-making discoveries that allow us to better understand ourselves and the world around us, but here at the Wyss, you don’t have to look hard to find many more women making history. See how women at the Wyss are shaping the future. https://lnkd.in/eQuau78B

Tomorrow is #InternationalWomensDay. As we celebrate, we also have to acknowledge that there are still many areas of gender inequality, including healthcare. The first step in closing the gender health gap is to acknowledge that the issue exists, but unfortunately, there are many barriers to open discussion about women’s health, such as embarrassment and stigma.?? ? So, we're taking the first step and opening up a dialogue. If we can’t talk openly about women’s health, we can’t advance women’s health.? Connect with the Wyss now to become part of our Women's Health Catalyst: https://lnkd.in/em3zKsdP #WomensHealth #WomenInSTEM

Members of the Wyss community recently returned from the Second Keystone Symposium on Drug Delivery to the Brain: Emerging Modalities. The event was co-organized by Wyss Senior Director of Translational R&D and Co-Lead of the Brain Targeting Program, James Gorman, M.D., Ph.D. and his colleague Stina Syv?nen. The?International Brain Barriers Society (IBBS) sponsored a poster award session, and Wyss Technology Development Fellow Ana Raquel P. Santa Maria, Ph.D., took home a prize. Learn more about the Wyss' Brain Targeting Program: https://lnkd.in/edGxNYe4

"As a periodontist in training, the possibility of bringing this revolutionary technology from benchtop to patient care appeared to be a great opportunity to solve unmet needs in our field," explains David T. Wu. When Wu started at Harvard, he learned about the tough gel adhesives being developed in the lab of Wyss Core Faculty member David Mooney. Because these strong adhesive patches work on wet surfaces and are not toxic to humans, he saw potential to use them for oral applications. Now, this technology is being translated into the clinic. https://lnkd.in/ezdxBd3N